Cendifensine
Cendifensine ( ) is a monoamine reuptake inhibitor (MRI) related to the amphetamines and cathinones which has not been marketed at this time.
≈ 1 min read
Cendifensine. encyclopegia.org, snapshot enwiki-001370376918. /a/cendifensine
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Cendifensine ( ) is a monoamine reuptake inhibitor (MRI) related to the amphetamines and cathinones which has not been marketed at this time. It was first described by 2013 and its was proposed in 2024.
The drug has been patented by Noema Pharma, which is developing a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) known as NOE-115 for the treatment of vasomotor symptoms associated with menopause as well as for binge-eating disorder and depressive disorders.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1370376918 under CC BY-SA 4.0; modifications have been made.